THERAPY WITH CHIMERIC ANTIGEN RECEPTOR T-CELLS. OVERVIEW OF CLINICAL EFFICACY AND PROSPECTS FOR IMPLEMENTATION IN KAZAKHSTAN
Main Article Content
Authors
G. Zauatbayeva
National Center for Biotechnology, Astana, Kazakhstan
M. Zhumabekova
National Center for Biotechnology, Astana, Kazakhstan
A. Shustov
National Center for Biotechnology, Astana, Kazakhstan
Abstract
Chimeric Antigen Receptor T-cell therapy (CAR-T) is a form of adoptive cellular immunotherapy.
This review aims to inform healthcare professionals - including regulatory experts in gene and cell therapy - about the principles of CAR-T therapy. It discusses the mechanisms of action, provides an overview of currently approved CAR-T products, and summarizes up-to-date clinical efficacy data. The article also outlines the current status of implementing CAR-T in Kazakhstan. Key technological and organizational factors are described which determine the prospect for the localization of CAR-T manufacturing and the launch of the clinical use in the country.
The use of CAR-T therapy is expanding around the world, but this therapy is not implemented in Kazakhstan.
Hallmarks of CAR-T technology include that CAR-T products are manufactured individually for patients and consist of genetically modified T-lymphocytes. Currently, CAR-T therapy is approved and recommended for the treatment of B-cell leukemia, lymphoma, and multiple myeloma, and the therapy is particularly efficient in patients with relapsed or refractory disease which do not respond to standard therapies.
Findings from the literature review highlight the strong potential of CAR-T therapy to improve treatment outcomes for patients with refractory forms of leukemia and lymphoma in Kazakhstan’s oncology centers.
Keywords
chimeric antigen receptor, CAR-T therapy, adoptive cellular immunotherapy, T-cells, leukemia, myeloma, cancer therapy, complete response rate
Article Details
References
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy // Science. – 2013. – Vol. 342, No. 6165. – P. 1432–1433. – DOI: 10.1126/science.342.6165.1432.
Barnes K. CAR T cells remain during long-term cancer remission // Commun Med (Lond). – 2022. – Vol. 2. – P. 28. – DOI: 10.1038/s43856-022-00092-w.
Ghorai S.K., Pearson A.N. Current Strategies to Improve Chimeric Antigen Receptor T (CAR-T) Cell Persistence // Cureus. – 2024. – Vol. 16, No. 7. – P. e65291. – DOI: 10.7759/cureus.65291.
Irving B.A., Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways // Cell. – 1991. – Vol. 64, No. 5. – P. 891–901. – DOI: 10.1016/0092-8674(91)90314-o.
Hirayama A.V., Gauthier J., et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells // Blood. – 2019. – Vol. 133, No. 17. – P. 1876–1887. – DOI: 10.1182/blood-2018-11-887067.
Amini L., Silbert S.K., et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion // Nat Rev Clin Oncol. – 2022. – Vol. 19, No. 5. – P. 342–355. – DOI: 10.1038/s41571-022-00607-3.
Fabrizio V.A., Boelens J.J., Mauguen A., et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy // Blood Adv. – 2022. – Vol. 6, No. 7. – P. 1961–1968. – DOI: 10.1182/bloodadvances.2023010269.
Lickefett B., Chu L., Ortiz-Maldonado V., et al. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle // Front Immunol. – 2023. – Vol. 14. – P. 1303935. – DOI: 10.3389/fimmu.2023.1303935.
Stuge T.B., Holmes S.P., Saharan S., et al. Diversity and recognition efficiency of T cell responses to cancer // PLoS Med. – 2004. – Vol. 1, No. 2. – P. e28. – DOI: 10.1371/journal.pmed.0010028.
Wang V., Gauthier M., Decot V., Reppel L., Bensoussan D. Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input // Cancers (Basel). – 2023. – Vol. 15, No. 4. – DOI: 10.3390/cancers15041003.
Fujiwara K., Masutani M., Tachibana M., Okada N. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties // Biochem Biophys Res Commun. – 2020. – Vol. 527, No. 2. – P. 350–357. – DOI: 10.1016/j.bbrc.2020.03.071.
Jayaraman J., Mellody M.P., Hou A.J., et al. CAR-T design: Elements and their synergistic function // EBioMedicine. – 2020. – Vol. 58. – P. 102931. – DOI: 10.1016/j.ebiom.2020.102931.
Mazinani M., Rahbarizadeh F. CAR-T cell potency: from structural elements to vector backbone components // Biomark Res. – 2022. – Vol. 10, No. 1. – P. 70. – DOI: 10.1186/s40364-022-00417-w.
Dotti G., Gottschalk S., Savoldo B., Brenner M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells // Immunol Rev. – 2014. – Vol. 257, No. 1. – P. 107–126. – DOI: 10.1111/imr.12131.
Davey A.S., Call M.E., Call M.J. The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities // Cancers (Basel). – 2020. – Vol. 13, No. 1. – DOI: 10.3390/cancers13010038.
Xiao X., Huang S., Chen S., et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies // J Exp Clin Cancer Res. – 2021. – Vol. 40, No. 1. – P. 367. – DOI: 10.1186/s13046-021-02148-6.
Li N., Li D., Pan J., Cachau R., Ho M. The IgG4 hinge with CD28 transmembrane domain mediates CAR dimerization and improves the activity of glypican 1-targeted CAR T cells in pancreatic cancer // Cancer Res. – 2022. – Vol. 82, Suppl. 12. – P. 549. – DOI: 10.1038/s41467-023-37616-4.
Cappell K.M., Kochenderfer J.N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains // Nat Rev Clin Oncol. – 2021. – Vol. 18, No. 11. – P. 715–727. – DOI: 10.1038/s41571-021-00530-z.
Boroughs A.C., Larson R.C., Marjanovic N.D., et al. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq // Mol Ther. – 2020. – Vol. 28, No. 12. – P. 2577–2592. – DOI: 10.1016/j.ymthe.2020.07.023.
Kawalekar O.U., O’Connor R.S., Fraietta J.A., et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells // Immunity. – 2016. – Vol. 44, No. 2. – P. 380–390. – DOI: 10.1016/j.immuni.2016.02.023.
Zhao X., Yang J., Zhang X., et al. Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia // Mol Ther Oncolytics. – 2020. – Vol. 18. – P. 272–281. – DOI: 10.1016/j.omto.2020.06.016.
Bethesda M. Cancer Stat Facts: Leukemia – Acute Lymphocytic Leukemia (ALL). – Bethesda: National Cancer Institute, 2024.
Ko R.H., Ji L., Barnette P., et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study // J Clin Oncol. – 2010. – Vol. 28, No. 4. – P. 648–654. – DOI: 10.1200/JCO.2009.22.2950.
Parker C., Waters R., Leighton C., et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial // Lancet. – 2010. – Vol. 376, No. 9757. – P. 2009–2017. – DOI: 10.1016/S0140-6736(10)62002-8.
Bajwa R., Schechter T., Soni S., et al. Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies // Bone Marrow Transplant. – 2013. – Vol. 48, No. 5. – P. 661–665. – DOI: 10.1038/bmt.2012.209.
Othman T., Logan A.C., Muffly L., et al. The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL // J Natl Compr Canc Netw. – 2024. – Vol. 22, No. 8. – DOI: 10.6004/jnccn.2024.7065.
Yang T., Dong Y., Zhang M., et al. Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia // Exp Hematol Oncol. – 2025. – Vol. 14, No. 1. – P. 2. – DOI: 10.1186/s40164-024-00593-5.
Davila M.L., Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies // Int J Hematol. – 2016. – Vol. 104, No. 1. – P. 6–17. – DOI: 10.1007/s12185-016-2039-6.
Lee D.W., Kochenderfer J.N., Stetler-Stevenson M., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial // Lancet. – 2015. – Vol. 385, No. 9967. – P. 517–528. – DOI: 10.1016/S0140-6736(14)61403-3.
Maude S.L., Frey N., Shaw P.A., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia // N Engl J Med. – 2014. – Vol. 371, No. 16. – P. 1507–1517. – DOI: 10.1056/NEJMoa1407222.
Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia // N Engl J Med. – 2013. – Vol. 368, No. 16. – P. 1509–1518. – DOI: 10.1056/NEJMoa1215134.
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL [Electronic resource]. – 2022. – Available at: URL (accessed: 01.05.2025).
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL [Electronic resource]. – 2022. – Available at: URL (accessed: 01.05.2025).
Rives S., et al. Tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Final analyses from the ELIANA study // Oral presentation at the 2022 Hybrid Congress of the European Hematology Association.
Turtle C.J., Hay K.A., Hanafi L.A., et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib // J Clin Oncol. – 2017. – Vol. 35, No. 26. – P. 3010–3020. – DOI: 10.1200/JCO.2017.72.8519.
Neelapu S.S., Jacobson C.A., et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma // Blood. – 2023. – Vol. 141, No. 19. – P. 2307–2315. – DOI: 10.1182/blood.2022018893.
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma [Electronic resource]. – 2021. – Available at: URL (accessed: 01.05.2025).
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 [Electronic resource]. – 2024. – Available at: URL (accessed: 01.05.2025).
Berdeja J.G., Madduri D., Usmani S.Z., et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study // Lancet. – 2021. – Vol. 398, No. 10297. – P. 314–324. – DOI: 10.1016/S0140-6736(21)00933-8.
Matous J., Biran N., Perrot A., et al. Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study // Blood. – 2023. – Vol. 142, Suppl. 1. – P. 1014. – DOI: 10.1182/blood-2023-187706.
Sidana S., Patel K.K., Peres L.C., et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma // Blood. – 2025. – Vol. 145, No. 1. – P. 85–97. – DOI: 10.1182/blood.2024025945.
San-Miguel J., Dhakal B., Yong K., et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma // N Engl J Med. – 2023. – Vol. 389, No. 4. – P. 335–347. – DOI: 10.1056/NEJMoa2303379.
CARVYKTI – CARTITUDE-4 (MMY3002) Study [Electronic resource]. – 2024. – Available at: URL (accessed: 01.05.2025).
CAR T-Cell Therapies Market Size to Uplift USD 88.51 Bn by 2034 [Electronic resource]. – 2025. – Available at: URL (accessed: 01.05.2025).
Approved CD19 CAR-T agents to treat over 13,000 cancer patients annually by 2031, driving sales of Breyanzi and Yescarta, says GlobalData [Electronic resource]. – 2023. – Available at: URL (accessed: 01.05.2025).
More than 150 Russian patients with blood cancer have received innovative CAR-T therapy [Electronic resource]. – 2025. – Available at: URL (accessed: 01.05.2025).
CAR-T therapy in Russia: an idle chimera or a real future? [Electronic resource]. – 2022. – Available at: URL (accessed: 01.05.2025).
The first CAR-T drug has been registered in Russia [Electronic resource]. – 2023. – Available at: URL 01.05.2025).
On approval of the rules for the use of advanced therapy medicinal products… Order of the Minister of Health of the Republic of Kazakhstan dated 08.12.2020 No. KR DSM-240/2020 [Electronic resource]. – 2020. – Available at: URL (accessed: 01.05.2025).
Francis N., Braun M., Neagle S., et al. Development of an automated manufacturing process for large-scale production of autologous T cell therapies // Mol Ther Methods Clin Dev. – 2023. – Vol. 31. – P. 101114. – DOI: 10.1016/j.omtm.2023.101114.
Luanpitpong S., Klaihmon P., Janan M., et al. Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic center in Thailand // Mol Ther Oncol. – 2024. – Vol. 32, No. 4. – P. 200889. – DOI: 10.1016/j.omton.2024.200889.
Palani H.K., Arunachalam A.K., Yasar M., et al. Decentralized manufacturing of anti-CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India // Bone Marrow Transplant. – 2023. – Vol. 58, No. 2. – P. 160–167. – DOI: 10.1038/s41409-022-01866-5.
Salazar-Riojas R., Alvarado-Navarro D.M., et al. Decentralized Point-of-Care Manufacturing of CD19 Chimeric Antigen Receptor T Cells in Mexico // JCO Glob Oncol. – 2025. – Vol. 11. – P. e2400581. – DOI: 10.1200/GO-24-00581.
Malakhova E., Pershin D., Kulakovskaya E., et al. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration // Cytotherapy. – 2024. – Vol. 26, No. 6. – P. 567–578. – DOI: 10.1016/j.jcyt.2024.02.025.
Maschan M., Caimi P.F., et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients // Nat Commun. – 2021. – Vol. 12, No. 1. – P. 7200. – DOI: 10.1038/s41467-021-27312-6.
Laetsch TW, Maude SL, Rives S, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial // J Clin Oncol. — 2023. — Vol. 41, № 9. — P. 1664–1669. — DOI: 10.1200/JCO.22.00642.
Novartis CAR T Tisagenlecleucel Continues Efficacy in Follicular Lymphoma in Long-Term Follow-Up [Electronic resource] // CGT Live. — 2023. —Available at: URL (accessed: 01.05.2025).
Tisa-cel Offers Durable Responses in R/R Follicular Lymphoma [Electronic resource] // Targeted Oncology. — 2023. —Available at: URL (accessed: 01.05.2025).
Yescarta Shows Durable Responses and Manageable Safety in Real-World R/R FL [Electronic resource] // CureToday. — 2024. —Available at: URL (accessed: 01.05.2025).
Axi-cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL [Electronic resource] // OncLive. — 2023. —Available at: URL (accessed: 01.05.2025).
Khvorost D, Kendall B, Jazirehi AR. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes // Cells. — 2024. — Vol. 13, № 8. — P. 662. — DOI: 10.3390/cells13080662.
BMS's Breyanzi shows high response rates in relapsed/refractory follicular lymphoma trial [Electronic resource] // Clinical Trials Arena. — 2024. —Available at: URL (accessed: 01.05.2025).
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3 [Electronic resource] // Bristol Myers Squibb. — 2023. —Available at: URL (accessed: 01.05.2025).
Analyzing Ide-cel's Trade-offs of Efficacy and Toxicity in Myeloma [Electronic resource] // Targeted Oncology. — 2023. —Available at: URL (accessed: 01.05.2025).
Dr. Phull on the Efficacy and Safety of Cilta-cel vs Ide-cel in R/R Multiple Myeloma [Electronic resource] // OncLive. — 2023. —Available at: URL (accessed: 01.05.2025).
Considering 3-Year Follow-up Data of Cilta-cel in Multiple Myeloma [Electronic resource] // Targeted Oncology. — 2024. —Available at: URL (accessed: 01.05.2025).